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doi:10.1016/j.jfma.2012.01.009Adrenalectomy is the definite treatment for aldosterone-producing adenoma (APA). Percuta-
neous ethanol or acetic acid injection with computed tomography (CT) guidance has been
described as a safe, noninvasive, and effective alternative treatment modality in patients with
high surgical risk. We report on a man who was 49 years of age and presented with treatment-
resistant hypertension and was later diagnosed with APA. CT-guided percutaneous ethanol
injection (PEI) was performed for this high surgical risk patient. He had aldosteronism recur-
rence 4 years after the ethanol injection, so a second PEI was performed. The tumor size
was reduced and his blood pressure was normalized. Therefore, we suggest that clinicians
should closely check aldosterone to renin ration and potassium level if percutaneous chemical
ablation is considered in functioning adrenal adenomas.
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Primary aldosteronism (PA), characterized by increased
aldosterone secretion from the adrenal glands, has been
increasingly recognized.1 Identification of aldosterone-
producing adenoma (APA), the surgically curable form of
secondary hypertension, is of paramount importance.1e4 In& Formosan Medical Association. All rights reserved.
Figure 2 The second computedetomography-guided percu-
taneous ethanol injection.
PEI in aldosterone-producing adenoma 177previous reports, percutaneous chemical ablation with
either acetic acid or ethanol for the treatment of APA was
considered as an effective modality for the nonsurgical
candidate.5 In this report, we first describe a patient with
adenoma recurrence 4 years after the percutaneous
ethanol injection (PEI). We suggest that intense follow-up
should be mandatory after PEI; a second PEI is also effec-
tive for the recurrence.
Case report
A man 49 years of age with treatment-resistant hyperten-
sion and intracranial hemorrhage was investigated for
secondary hypertension. Low potassium level and an
elevated aldosterone to renin ratio (ARR) made the PA
likely [plasma aldosterone concentration (PAC) 85.5 ng/dL,
plasma renin activity (PRA), 0.16 ng/mL/hr and ARR,
534.4]. An abdominal computed tomography (CT) showed
a 1-cm tumor at the right adrenal gland with Stanford type
II aortic dissection. An adrenal venous sampling (AVS)
revealed the lateralization of aldosterone hypersecretion.
CT-guided percutaneous ethanol injection (PEI) with 10 mL
of 99.8% ethanol to adrenal adenoma was thus performed
for the safety of aortic dissection. In the following 3 years,
the patient’s blood pressure was kept normotensive with
spironolactone use. He had normal serum potassium level
and ARR < 35.
Four years after the PEI, the patient’s systolic blood
pressure elevated to higher than 160 mmHg. The positive
plasma ARR measurement and saline infusion test
confirmed the diagnosis of PA again. The saline infusion test
was performed with intravenous infusion of 2 L of 0.9%
saline for 4 hours. The serum aldosterone before and after
saline infusion were 93.9 and 65.5 ng/dL, respectively. The
abdominal CT revealed a 1.2-cm, hypodense tumor at the
right adrenal gland (Fig. 1). The second PEI was performed
(Fig. 2), which treated the patient’s hypertension and
normalized his ARR. Follow-up abdominal magnetic reso-
nance imaging showed a reduced tumor size (Fig. 3).
Discussion
In recent reports,3,4 the prevalence of primary aldoste-
ronism in the newly diagnosed hypertension has exceeded
10%, with 4.8% of surgically curable APA Aldosterone itself
is a cardiovascular risk, making the accurate diagnosis ofFigure 1 The computed tomography scan revealed a hypo-
dense tumor at the right adrenal gland (arrow) 4 years after
the first percutaneous ethanol injection.APA and timely surgery more important. The Endocrine
Society Clinical Practice Guidelines5 recommend unilateral
laparoscopic adrenalectomy in patients with documented
unilateral PA and medical treatment with a mineralocorti-
coid receptor (MR) antagonist in patients unable or
unwilling to undergo surgery. Less invasive techniques,
including radiofrequency ablation (RFA), transcatheter
arterial embolization (TAE), and chemical ablation (injec-
tion of ethanol or acetic acid) have been described as
alternative modalities for the nonsurgical candidate.5
PEI has been widely used in small hepatocellular carci-
noma (HCC), and the survival rates of surgical resection and
PEI are comparable.6 The application of PEI in nodular
lesion of endocrine glands, including thyroid, parathyroid,
and adrenal glands, has also been proposed.6 A retrospec-
tive study evaluated the effectiveness of CT-guided
percutaneous chemical ablation of adrenal neoplasms
under CT guidance.7 Of the seven patients with PA, all
reached the normal range of serum potassium level, PAC,Figure 3 The T1-weighted image of abdominal magnetic
resonance imaging showed a contracted tumor.
178 F.-C. Chang et al.and PRA during the first 2 years. Percutaneous chemical
ablation may be a good method in patients with high
surgical risk. Ethanol and acetic acid are the most
commonly agents used for chemical ablation.6,7 The
mechanism of action is cytoplasmic dehydration followed
by coagulation necrosis, fibrous reaction, and microvas-
cular thrombosis. The difference is that the ethanol has
difficulty in penetrating tumor septa well and is used in
small tumors (<3 cm). In achieving the same degree of
tumor damage, a larger volume of ethanol is needed.
However, the patients experienced less abdominal pain
with ethanol injection compared with acetic acid.7 In the
previous report,6 percutaneous acetic acid injection (PAI)
for primary aldosteronism attributable to APA has a good
outcome with a mean follow-up period of 42.4 months.6
Ethanol was chosen in our patient for a small adrenal
tumor.
Our patient had aldosteronism recurrence 4 years after
the PEI. Although PEI has been a noninvasive, simple, and
cost-effective treatment for small functional adrenal
cortical tumors, the role of surgical adrenalectomy in
adrenal neoplasms cannot be replaced.5 If surgery is not
feasible or suitable, more efficient chemical agents such as
acetic acid may be considered for chemical ablation with
intensive follow-up. With evidence of adenoma recurrence
during the follow-up period,8 it was mandatory and effec-
tive to perform the second injection. Our case is the first
report to show the effectiveness of repeated PEI in control
of APA if an alternative strategy, except adrenalectomy, is
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